Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women

被引:1
|
作者
Luengratsameerung, S. [1 ]
Panyakhamlerd, K. [1 ]
Treratanachat, S. [2 ]
Taechakraichana, N. [1 ]
机构
[1] Chulalongkorn Univ, Reprod Med Div, Dept Obstet & Gynecol, Menopause Res Unit,Fac Med, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Div Gynecol Pathol, Dept Obstet & Gynecol, Fac Med, Bangkok 10330, Thailand
关键词
CONJUGATED EQUINE ESTROGEN; VAGINAL CREAM; BONE TURNOVER MARKERS; POSTMENOPAUSE; VULVOVAGINAL ATROPHY; HORMONE REPLACEMENT THERAPY; BIOCHEMICAL MARKERS; MINERAL DENSITY; LOCAL ESTROGEN; ESTRADIOL; EFFICACY; CALCIUM; 17-BETA-ESTRADIOL; RALOXIFENE; MANAGEMENT;
D O I
10.3109/13697137.2012.662252
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To evaluate the systemic effect of therapy with conjugated equine estrogen (CEE) vaginal cream on bone turnover markers in postmenopausal women. Methods This study was conducted in 40 spontaneously menopausal women aged 40-60 years who complained of vulvovaginal symptoms. Subjects were instructed to self-administer 1 g CEE vaginal cream (CEE 0.625 mg) once daily for 12 weeks (continuous phase), then twice weekly for the next 12 consecutive weeks (intermittent phase). Serum levels of bone turnover markers and estradiol and the vaginal maturation index were evaluated at baseline, 12 and 24 weeks after treatment initiation. Results Levels of C-terminal cross-linked telopeptide of type I collagen (CTx) were significantly decreased at 12 weeks and 24 weeks when compared to baseline values (median (range) 0.435 (0.171-0.859) and 0.391 (0.122-0.714) vs. 0.562 (0.250-1.290) ng/ml (p < 0.001 and < 0.001), respectively), but there was no significant difference between the levels at 12 and 24 weeks. Levels of procollagen type I N-terminal propeptide (P1NP) and osteocalcin levels were significantly decreased after 24 weeks when compared to pretreatment levels (mean (standard deviation) 41.74 (11.76) vs. 50.02 (17.71) ng/ml (p = 0.002) for P1NP and 23.91 (7.11) vs. 27.54 (8.67) ng/ml (p < 0.001) for osteocalcin, respectively). Estradiol levels were significantly increased and the vaginal maturation index was significantly improved after 12 and 24 weeks when compared to baseline. Conclusions CEE vaginal cream significantly decreased the bone resorption marker (CTx) in postmenopausal women after completion of the continuous-treatment phase. There was no significant further decrease after the intermittent phase. The effects on the markers of bone formation and bone turnover (P1NP and osteocalcin) were apparent only at 24 weeks. The two treatment phases moderately increased serum estradiol levels and significantly improved the vaginal maturation index.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 50 条
  • [41] A randomized comparative study of vaginal estrogen cream in postmenopausal women with overactive bladder syndrome
    Tseng, L. H.
    Liang, C. C.
    Chang, Y. L.
    Soong, Y. K.
    Wang, A.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2007, 18 : S15 - S16
  • [42] Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis
    Eastell, Richard
    Reid, David M.
    Vukicevic, Slobodan
    Ensrud, Kristine E.
    LaCroix, Andrea Z.
    Thompson, John R.
    Thompson, David D.
    Cummings, Steven R.
    BONE, 2012, 50 (05) : 1135 - 1140
  • [43] COMPARISON OF TRANSDERMAL AND SUBCUTANEOUS TERIPARATIDE EFFECTS ON MARKERS OF BONE TURNOVER AND SAFETY IN POSTMENOPAUSAL WOMEN
    Kenan, Y.
    Kochba, E.
    Shahar, M.
    Gadasi, H.
    Levin, G.
    Foldes, A. J.
    Ish-Shalom, S.
    Matsumoto, T.
    Lindsay, R.
    Christiansen, C.
    Neer, R.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 178 - 178
  • [44] Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
    Paul E Goss
    Peyman Hadji
    Milayna Subar
    Paula Abreu
    Torben Thomsen
    Jose Banke-Bochita
    Breast Cancer Research, 9
  • [45] Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
    Goss, Paul E.
    Hadji, Peyman
    Subar, Milayna
    Abreu, Paula
    Thomsen, Torben
    Banke-Bochita, Jose
    BREAST CANCER RESEARCH, 2007, 9 (04)
  • [46] The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
    Marcus, R
    Holloway, L
    Wells, B
    Greendale, G
    James, MK
    Wasilauskas, C
    Kelaghan, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (09) : 1583 - 1595
  • [47] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Atmaca, Aysegul
    Gedlik, Olcay
    ADVANCES IN THERAPY, 2006, 23 (06) : 842 - 853
  • [48] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Aysegul Atmaca
    Olcay Gedik
    Advances in Therapy, 2006, 23 : 842 - 853
  • [49] Differential time-related effects of conjugated equine estrogen on bone metabolism in oophorectomized women
    Nozaki, M
    Inoue, Y
    Hashimoto, K
    Ogata, R
    Nakano, H
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1998, 60 (01) : 41 - 46
  • [50] Relationship of bone mineral density and biochemical markers of bone turnover in postmenopausal women
    Vuceljic, M
    Vucetic, D
    Mihajlovic, R
    Ilic-Stojanovic, O
    Nikolajevic, R
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S136 - S137